DGI-021 Cost-Efficacy Analysis of Abiraterone For the Treatment of Hormone-Refractory Metastatic Prostate Cancer Patients | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Drug information (i. anti-infectives, ii. cytostatics, iii. others)

DGI-021 Cost-Efficacy Analysis of Abiraterone For the Treatment of Hormone-Refractory Metastatic Prostate Cancer Patients

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Alcobia A, Soares A

DGI-021 Cost-Efficacy Analysis of Abiraterone For the Treatment of Hormone-Refractory Metastatic Prostate Cancer Patients

European Journal of Hospital Pharmacy 2013;20:A103.